Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS-Reference-Cited by-同舟云学术

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Published:2014-12-11 Issue:25 Volume:124 Page:3817-3827
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kanakry Christopher G.¹,Tsai Hua-Ling¹,Bolaños-Meade Javier¹,Smith B. Douglas¹,Gojo Ivana¹,Kanakry Jennifer A.¹,Kasamon Yvette L.¹,Gladstone Douglas E.¹,Matsui William¹,Borrello Ivan¹,Huff Carol Ann¹,Swinnen Lode J.¹,Powell Jonathan D.¹,Pratz Keith W.¹,DeZern Amy E.¹,Showel Margaret M.¹,McDevitt Michael A.¹,Brodsky Robert A.¹,Levis Mark J.¹,Ambinder Richard F.¹,Fuchs Ephraim J.¹,Rosner Gary L.¹,Jones Richard J.¹,Luznik Leo¹

Affiliation:

1. Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD

Abstract

Key Points Posttransplantation cyclophosphamide is effective as sole GVHD prophylaxis for myeloablative HLA-matched–related or –unrelated BMT. Despite low chronic GVHD with PTCy, relapse and survival are comparable with outcomes reported using other GVHD prophylactic approaches.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/25/3817/1465180/3817.pdf

Reference53 articles.

1. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.;Weiden;N Engl J Med,1981

2. Graft-versus-leukemia reactions after bone marrow transplantation.;Horowitz;Blood,1990

3. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.;Weisdorf;Biol Blood Marrow Transplant,2012

4. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.;Bhatia;Blood,2007

5. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.;Ratanatharathorn;Blood,1998

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus;Transplantation Proceedings;2024-09

2. Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide;Bone Marrow Transplantation;2024-08-24

3. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention;Blood Advances;2024-08-15

4. Stem Cell Treatment for Acute Lymphoblastic Leukemia in Adults;Journal of Regenerative Medicine & Biology Research;2024-08-13

5. Improved Outcome of Allogeneic Transplantation in Older Patients Treated for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Reduced Duration of Immune Suppression;Transplantation and Cellular Therapy;2024-08